Sandoz has announced FDA approval for their two interchangeable biosimilars of denosumab - Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) based on reference products Xgeva and Prolia https://t.co/Spb0ABOMMm https://t.co/wkMurvB0G3
Links:
Sandoz receives FDA approval for first and only denosumab biosimilars
https://bit.ly/3PBM1QP
Mar-09-2024
